Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
UPIIIa CRISPR/Cas9 KO Plasmid (h): sc-401796
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UPIIIa CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UPIIIa genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UPIIIa Antibody (C-6): sc-166808
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UPIIIa CRISPR/Cas9 KO Plasmid (h) | sc-401796 | 20 µg | $397.00 |
Overview
UPK3A encodes uroplakin IIIa (UPIIIa), a tetraspanin-like integral membrane component of the uroplakin plaques that strengthen the apical surface of differentiated urothelial umbrella cells. UPIIIa assembles with other uroplakins to organize specialized membrane domains that support barrier function, surface differentiation, and mechanical resilience during bladder filling and voiding. Through its role in epithelial polarity and membrane protein trafficking, UPK3A contributes to urothelial homeostasis and responses to injury. Altered uroplakin expression patterns are frequently examined as molecular features of urothelial differentiation status in studies of bladder pathology and epithelial remodeling.
UPIIIa CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UPK3A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UPK3A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UPK3A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UPIIIa protein expression.
This CRISPR knockout system enables efficient generation of UPK3A-deficient cell models for investigation of UPIIIa signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting UPK3A exon(s) critical for UPIIIa function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple UPK3A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UPIIIa CRISPR/Cas9 KO Plasmid (h) and UPIIIa CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UPK3A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UPIIIa HDR Plasmid (h) and UPIIIa HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UPK3A homology arms to support homology-directed repair at defined UPK3A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.